Skip to content
Putting patients first: Why PBM reform must ensure that middlemen pass along 100% of rebates
This is the first in a series of Bio.News articles looking at the need for pharmacy benefit manager (PBM) reform through the lens of […]
Federal Policy
How utilization management blocks patient access
Insurers and pharmacy benefit managers (PBMs) in search of profits are preventing patients from getting the drugs they need, according to the latest episode
How utilization management blocks patient access Read More »
CMS must address Part D plan abuse of IRA provisions designed to protect patient access
The Biotechnology Innovation Organization (BIO) has once again requested that the Centers for Medicare & Medicaid Services (CMS) take steps to protect patient access,
CMS must address Part D plan abuse of IRA provisions designed to protect patient access Read More »
CPAC supports FTC action against pharmacy benefit managers
Despite frequent criticism of the Federal Trade Commission (FTC), the Conservative Political Action Conference (CPAC) has announced its support for FTC efforts to rein in pharmacy
CPAC supports FTC action against pharmacy benefit managers Read More »
Open enrollment can be a ‘House of Horrors’: 4 monsters for patients to beware
October is the scariest time of year. Young goblins walk the streets demanding treats, local haunted houses are packed full of fright-chasing teens, and
Open enrollment can be a ‘House of Horrors’: 4 monsters for patients to beware Read More »
Skyrocketing 340B program spending must prompt more hospital accountability
The 340B program grew by 24% in 2023, according to new figures from the government’s Health Resources and Services Administration. Sales at discounted prices
Skyrocketing 340B program spending must prompt more hospital accountability Read More »
A family, a firm, and a foundation fighting rare disease join BIO’s podcast
A family battling rare disease, a biopharma startup they’re assisting, and an organization seeking congressional support for new rare disease drugs share their journeys
A family, a firm, and a foundation fighting rare disease join BIO’s podcast Read More »
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’
The search for safer, effective replacements for opioids is a critical public health priority, but that effort is being undermined by the Inflation Reduction
Development of non-opioid pain medicines threated by IRA’s ‘pill penalty’ Read More »
BIF 2024: ‘The IRA really disrupted how we think’
The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the
BIF 2024: ‘The IRA really disrupted how we think’ Read More »
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American seniors they serve –